You are here

Truvada Is Underused for Prevention of HIV

Only an estimated 22,000 have taken the medication for prophylaxis

Truvada was approved for pre-exposure prophylaxis (PrEP) as a daily medication that those at high risk for human immunodeficiency virus (HIV) could take to protect against the virus causing AIDS in 2012. However, an analysis has found that less than 22,000 people have taken PrEP for prevention.

According to the Wall Street Journal, the Centers for Disease Control and Prevention (CDC) released a report suggesting some 1.2 million U.S. adults who are at substantial risk for acquiring HIV could benefit from PrEP. Among those are one in four gay and bisexual men; one in five people who inject drugs; and one in 200 sexually active heterosexuals.

Taking PrEP reduces the risk of HIV infection through sexual transmission by as much as 92% and among people who inject drugs by about 70%, the CDC says. Still, one in three primary care doctors haven’t heard of the medication, according to a CDC survey.

“More high-risk individuals need to know about the benefits of PrEP and more physicians need to know about it,” said Carlos del Rio, chairman of the Infectious Disease Society of America’s HIV Medicine Association and a professor at Emory University. “We can really decrease the number of new HIV infections if PrEP is used more.”

PrEP can cost between $8,000 and $14,000 a year, although it is covered by most private insurers and by Medicaid in many states. Assistance programs, including one from Gilead Sciences, the maker of Truvada, are available for those without insurance. The drug, which is also used in HIV treatment, has mostly minimal side effects, doctors say.

Some AIDS organizations don’t promote use of the drug, partly out of concern it could encourage more risky sexual behavior. “We are having an explosion of other sexually transmitted diseases impacting the gay community and PrEP offers no protection whatsoever for any other disease,” said Ged Kenslea, communications director for the AIDS Healthcare Foundation, a Los Angeles-based global AIDS organization.

Kenslea said the group disagrees with the CDC’s goal of getting 1.2 million people on PrEP. “The patient must take the [PrEP] pill; we can’t even get people who are already HIV-positive to take their pills every day,” he said. The foundation last week began a national advertising campaign, entitled “PrEP: The Revolution That Didn’t Happen,” in gay and lesbian publications in major cities. It aims in part to encourage the CDC to focus on other prevention methods, such as condoms, and to devote its resources to HIV treatment.

Researchers at Kaiser Permanente in California followed 657 noninfected people taking PrEP for an average of seven months and found none of the participants contracted HIV, said Jonathan Volk, lead author of the study and a physician with Kaiser Permanente San Francisco Medical Center. “That’s really compelling data on how effective this medication is,” he said.

After one year on PrEP, however, about half of the users were diagnosed with at least one sexually transmitted disease. And nearly half the participants in a representative subset said they used condoms less frequently after starting PrEP, Dr. Volk said. The study was published in September in the journal Clinical Infectious Diseases.

Albert Liu, a clinical research director at the San Francisco Department of Public Health, said a study he led shows that most people will take PrEP as prescribed if they have access to the medication. San Francisco has made efforts to expand the availability of PrEP over the past year, including offering it in a number of clinics.

The study, published in November in JAMA Internal Medicine, followed 557 gay men and transgender women who were provided PrEP for a year in clinics in San Francisco and Miami and a community health center in Washington, D.C. More than 80% of the participants had protective levels of PrEP in their bloodstream, suggesting a high level of adherence to the medication regimen, Dr. Liu said. The study also found that among the participants, “risky behavior either declined or remained the same,” he said.

“My belief is that PrEP doesn’t change people’s behavior,” said Paul Marcelin, a 41-year-old software engineer in Alameda, California, who has been taking the drug since July 2013.

Source: Wall Street Journal, December 21, 2015.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020